Ondine President increases shareholding
Nicolas Loebel, President and CTO, purchased 25,000 shares at 12.6 pence per share.
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Nicolas Loebel, President and CTO, has purchased 25,000 shares ("Common Shares") in the Company at a price of 12.6 pence per Common Share on 05 February 2025.
Following this transaction, Nicolas Loebel holds 3,538,991 Common Shares representing 0.8006% of the issued share capital of the Company.
About Ondine Biomedical Inc.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Nicolas Loebel |
| 2. | Reason for the Notification | |
| a) | Position/status | President and CTO (PDMR) |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Ondine Biomedical Inc. |
| b) | LEI | 9845005B69E07CGF4A56 |
| a) | Description of the Financial instrument, type of instrument | Common shares |
| Identification code | ISIN: CA68234M2058 | |
| b) | Nature of the transaction | Share purchase |
| c) | Price(s) and volume(s) | 25,000 shares at 12.6 pence each |
| d) | Aggregated information: ·Aggregated volume ·Price | N/A |
| e) | Date of the transaction | 05 February 2025 |
| f) | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.